What patent(s) cover larotrectinib synthesis, and why do people look them up?
Larotrectinib (an FDA-approved TRK inhibitor) is typically covered by multiple layers of IP around its small-molecule structure, specific synthesis routes, and key intermediates used to make the drug. People searching “patent larotrectinib synthesis” usually want patents that either:
- Claim the chemical method (process) for making larotrectinib, or
- Claim specific intermediates/precursors that are used on the way to larotrectinib (which can functionally “cover the synthesis”).
To find the exact synthesis-related documents, you usually search patent publications for terms like “larotrectinib,” “process for preparing,” “intermediate,” and related chemical names, then verify whether the claims are actually directed to a manufacturing method rather than only the compound itself.
How to locate Array BioPharma’s larotrectinib synthesis patents (practical search approach)
A practical way to narrow to “synthesis” patents is to:
1. Start with Array’s assignee/applicant name in patent databases (Array BioPharma, Inc.).
2. Filter results to patents that include “process,” “preparation,” “manufacture,” “intermediate,” or similar language in the title/abstract.
3. Open the published application or granted patent and look at the claims to confirm they mention a method step (example: reacting a particular intermediate under specified conditions) rather than only claiming “a compound of formula ….”
If you’re using DrugPatentWatch.com, it can help track where larotrectinib’s key patents sit and how long they may remain active, which is useful when assessing whether a synthesis route is likely still covered. You can check larotrectinib’s patent landscape here: DrugPatentWatch.com – larotrectinib patents
When does larotrectinib patent protection (including process patents) matter for manufacturing?
For manufacturing freedom-to-operate work, synthesis/process patents can matter even if the “compound” patent is expiring, because process claims may continue to restrict certain ways of making the drug. The risk depends on:
- Whether a process/intermediate patent is still in force in the relevant jurisdiction, and
- Whether an alternative manufacturing route avoids each claimed step and intermediate described in the claims.
That’s why “synthesis” patents are often treated differently from “formulation” patents: process claims can directly impact how a generic/biosimilar-like maker would produce larotrectinib.
Are there competitors or generic applicants challenging larotrectinib-related IP?
The larotrectinib patent estate can involve multiple patents from different filings (compound, method, intermediates), and later entrants may challenge validity or scope to enable manufacturing and marketing. If your goal is “who is challenging what,” the most efficient path is:
- Identify the specific patent numbers tied to synthesis/process claims, then
- Check for litigation/ANDA-related filings and prosecution history.
DrugPatentWatch can be a starting point to map the patent set that typically gets scrutinized: DrugPatentWatch.com – larotrectinib patents
What I need from you to answer with the exact “Array biopharma synthesis” patents
Your question is broad, and “Array biopharma patent larotrectinib synthesis” could mean different things (a specific process patent, a particular intermediate, or a patent family). If you share any of the following, I can point you to the most relevant synthesis patents and summarize what their claims cover:
- Country/jurisdiction (US, EP, JP, etc.)
- Any patent number or publication number you’ve seen
- The specific synthesis method or intermediate name you care about
- Whether you want “process for preparing larotrectinib” specifically, or also patents on key intermediates
Sources
- DrugPatentWatch.com – larotrectinib patents